Mode
Text Size
Log in / Sign up

Short-chain fatty acids and intestinal macrophages modulate metabolism in metabolic syndrome and obesityShort Chain Fatty Acids May Help Manage Metabolic Syndrome

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the role of the SCFA-intestinal macrophage axis in metabolism, though human gut data remains limited.

This narrative review explores the role of short-chain fatty acids (SCFAs), including butyrate, acetate, and propionate, in modulating intestinal macrophage function and systemic metabolic homeostasis. The review synthesizes evidence on how these SCFAs regulate glycolysis, mTOR-associated metabolism, and HDAC-dependent inflammatory programs. Additionally, it examines how acetate and propionate influence inflammasome activity, cytokine production, and receptor signaling.

The authors note that while the SCFA-intestinal macrophage axis is a significant pathway in metabolic syndrome, obesity, and insulin resistance, the clinical impact of fiber, microbiota-directed interventions, and SC1FA delivery remains variable. These outcomes are influenced by specific formulations, delivery routes, and the baseline metabolic state of the individual.

A primary limitation noted is that most current mechanistic evidence is derived from extraintestinal macrophages, and in situ evidence from the human gut remains scarce. Consequently, while the biological mechanisms are promising, the clinical translation of these findings for metabolic disorders is currently limited by the lack of human-specific data.

How this fits prior evidence

This review addresses a gap in the current evidence regarding the specific mechanisms of the SCFA-intestinal macrophage axis in metabolic syndrome and obesity. While prior coverage noted that faecal microbiota transplantation did not significantly reduce HOMA-IR in patients with metabolic disorders, this review explores the underlying cellular mechanisms of SCFAs. It also relates to the role of gut microbiome dysbiosis in hypertension and metabolic syndrome, though it focuses on the specific immunometabolic signaling of butyrate, acetate, and propionate.

This review looks at how short-chain fatty acids (SCFAs) affect the body, specifically focusing on conditions like obesity, hypertension, and insulin resistance. These fatty acids, which include butyrate, acetate, and propionate, are produced during the digestion of fiber. The research highlights how these compounds may influence the way immune cells in the gut respond to inflammation and manage metabolism.

Researchers found that butyrate can regulate specific metabolic pathways and inflammatory programs. Acetate and propionate were also linked to changes in cytokine production and cellular metabolism. These findings suggest that the interaction between SCFAs and gut cells could play a role in maintaining metabolic balance.

It is important to note that much of this information comes from studies on cells outside the human gut, and there is currently limited evidence from human gut studies. Additionally, the effects of fiber and SCFA delivery vary depending on the specific formula and the individual's health status. Because of these factors, the results are not yet ready to change standard medical treatments.

What this means for you:
SCFAs may influence metabolism and inflammation, but more human gut research is needed to confirm clinical effects.

Common questions

What are short-chain fatty acids?

Short-chain fatty acids (SCFAs) include butyrate, acetate, and propionate. These compounds are produced during the digestion of fiber and are known to influence immune cell function, inflammatory programs, and cellular metabolism in the body.

How do these fatty acids affect metabolic health?

Butyrate can regulate glycolysis and inflammatory programs, while acetate and propionate can affect cytokine production and receptor signaling. These processes are linked to conditions like obesity, hypertension, and insulin resistance.

Can fiber or SCFA supplements treat metabolic syndrome?

The review shows that the effects of fiber and SCFA delivery are variable. Their impact depends on the specific formulation, the route of delivery, and the individual's baseline metabolic state. Talk to your doctor about these options.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Chronic low-grade inflammation (CLGI) is a major feature of metabolic syndrome (MetS), and the intestinal mucosa is an important site where microbial metabolites interact with host immunity. Intestinal lamina propria macrophages (LpMs) maintain mucosal tolerance, barrier homeostasis, and antimicrobial defense, and their phenotype and metabolism are altered in obesity and related metabolic disturbances. Short-chain fatty acids (SCFAs), generated mainly by microbial fermentation of dietary fiber, influence macrophage function through intracellular metabolism, G protein-coupled receptor signaling, and histone deacetylase inhibition. Butyrate is the best-characterized SCFA in this context and regulates glycolysis, mTOR-associated metabolism, antimicrobial responses, and HDAC-dependent inflammatory programs. Acetate and propionate also affect inflammasome activity, cytokine production, receptor signaling, and cellular metabolism. These mechanisms connect microbial metabolism with intestinal inflammation, epithelial barrier function, and systemic metabolic homeostasis. In obesity and insulin resistance, colonic macrophage recruitment and metabolic remodeling are closely associated with disease progression, whereas macrophage-related effects in metabolic dysfunction-associated steatotic liver disease and hypertension involve broader gut–liver, vascular, and renal pathways. Human studies of dietary fiber, microbiota-directed interventions, and SCFA delivery show variable cardiometabolic effects, with outcomes influenced by formulation, route, and baseline metabolic state. Given that most current mechanisms are derived from extraintestinal macrophages and in situ evidence from the human gut remains scarce, this narrative review summarizes the homeostatic biology of intestinal macrophages, the pathways through which SCFAs regulate their immunometabolism, the context-dependent relevance of this axis across MetS components, and the barriers to clinical translation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.